Last reviewed · How we verify
GSK1605786 GSK tablet: formulation E — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK1605786 GSK tablet: formulation E (GSK1605786 GSK tablet: formulation E) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK1605786 GSK tablet: formulation E TARGET | GSK1605786 GSK tablet: formulation E | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK1605786 GSK tablet: formulation E CI watch — RSS
- GSK1605786 GSK tablet: formulation E CI watch — Atom
- GSK1605786 GSK tablet: formulation E CI watch — JSON
- GSK1605786 GSK tablet: formulation E alone — RSS
Cite this brief
Drug Landscape (2026). GSK1605786 GSK tablet: formulation E — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk1605786-gsk-tablet-formulation-e. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing